Shares of Century Therapeutics Inc IPSC zoomed by 20.74% to $1.63 per share on Wednesday, which is the best value transfer in almost a month since Oct. 1. The shares additionally rose probably the most in over 11 months since Dec. 6, 2023, in a single day.
Additionally learn: Trump’s Tariff Menace To Canada Might Disrupt Oil Markets, Inflate Costs: ‘Would Possible Increase The Worth Of Fuels,’ Says Analyst
What Occurred: On Wednesday, Casdin Capital acquired a further 1,380,000 shares in Century Therapeutics elevating its stake by almost 43% within the biotechnology firm, as per an SEC submitting.
After the transaction, Casdin Capital owns a complete of 4,592,316 shares, or 5.4% in Century Therapeutics. Based on the submitting, Century shares had been acquired for $1.35 apiece. Century Therapeutics represents 0.12% of Casdin’s portfolio after the transaction.
Why It Issues: Century shares jumped by almost 21%, probably the most in a single day since Dec. 6, 2023, when it had jumped by 36% after the transaction.
Casdin Capital, LLC, a New York-based funding agency, makes a speciality of biotechnology investments. With a $1.5 billion fairness portfolio, its prime holdings embody BioLife Options Inc (BLFS) and Sarepta Therapeutics Inc (SRPT).
Picture by way of Unsplash
Learn Subsequent:
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
